Intellia Announces FDA Acceptance of BLA for Lonvo-z with PDUFA Date March 10, 2027
Intellia Therapeutics announced FDA acceptance of its BLA for lonvo-z, a CRISPR-based therapy, with a Priority Review and PDUFA action date of March 10, 2027. The FDA does not plan to hold an advisory committee. If approved, lonvo-z would be the first in vivo CRISPR therapy, supported by Phase 3 data showing an 87% reduction in mean monthly attacks and a 62% attack-free rate.
How this was made
The 30-second read
Why it matters
The acceptance removes a major regulatory hurdle, setting a clear timeline for a decision and likely prompting investor buying.
Market read
Regulatory progress for a novel gene‑editing therapy can drive significant price movement in NTLA and influence sentiment across biotech peers.
What to watch
Potential competition from other HAE treatments and reimbursement uncertainties.
Background
Intellia filed an 8‑K announcing FDA acceptance of its BLA for lonvo‑z, a first‑in‑vivo CRISPR therapy for hereditary angioedema.
Ticker impact
Intellia Therapeutics received FDA acceptance of its BLA for lonvo‑z with Priority Review and a PDUFA date of March 10, 2027.
Potential short‑term upside of 5‑10% as investors price in the chance of approval.
Biotech stocks typically rally on FDA acceptance; the therapy targets a rare disease with strong Phase 3 data.
Market effects
Positive signal for the CRISPR gene‑editing sector and rare‑disease therapeutics.
U.S. biotech market may see modest uplift.
Highlights progress in in‑vivo CRISPR therapies worldwide.
Counterpoint
If the FDA later requests additional data, the initial rally could reverse.
Key entities
- companyIntellia Therapeutics, Inc.
Biotech firm developing CRISPR‑based therapies.
- regulatorFDA
U.S. Food and Drug Administration overseeing drug approvals.
